Aziyo Biologics reports record annual net sales of ~$49M, Q4 up 15-17% YoY

ELUTIA INC.

2022-FY EPS reported -$2.38 revenue$49,187,000

Preliminary Q4 2022 net sales of ~$12.5-12.7M, up 15-17% vs Q4 2021.
Full year 2022 record net sales of ~$49.0-49.2M, up 3-4% YoY; up ~15-16% excluding $4.9M discontinued product.
SimpliDerm and CanGaroo combined Q4 net sales expected to grow ~30% vs Q4 2021.
Company raised $15.2M in gross proceeds from recent financings; awaits FDA clearance for CanGaroo RM.
CEO cites strong team performance; full Q4 and FY results expected in early March 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported fourth quarter ended December 31, 2022 results: revenue approximately $12.5-$12.7 million.

Period: fourth quarter ended December 31, 2022
Revenue: approximately $12.5-$12.7 million
Result: preliminary results

Exact text from the filing

Anticipate fourth quarter 2022 net sales of approximately $12.5-$12.7 million, an increase of 15%-17% compared to the same prior year period

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported full year ended December 31, 2022 results: revenue approximately $49.0-$49.2 million.

Period: full year ended December 31, 2022
Revenue: approximately $49.0-$49.2 million
Result: preliminary results

Exact text from the filing

Anticipate full year 2022 record net sales of approximately $49.0-$49.2 million, an increase of 3%-4% compared to the prior year and , after excluding 2021 sales of a discontinued product of $4.9 million, an increase of approximately 15%-16%

View on SEC.gov

Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-002078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.